by Gabriel Levitt, President, PharmacyChecker.com and Prescription Justice | Jan 30, 2018 | Drug Importation
The Utah State Capitol
Utah State Representative Norman Thurston (R-64) has introduced legislation that would allow pharmacy wholesalers in Utah to import lower-cost pharmaceuticals to be sold within state lines. The bill’s goal is to lower the growing burden of prescription drug costs on the Utah budget and reduce out-of-pocket costs for Utah residents. The legislation is largely based on model state drug importation legislation drafted by the National Academy for State Health Policy (NASHP).
The bill, H.B. 163, “The Canadian Prescription Drug Importation Act,” differs substantially from past state-based initiatives, legislation, and laws on prescription drug importation. The most pronounced difference is that it seeks formal approval from the federal government to import medication from Canada. Past state laws on drug importation sought to circumvent federal regulations, such as in Maine, where the law was overturned in 2015. (more…)
Tagged with: azar, nashp, state, thurston, utah
by Gabriel Levitt, President, PharmacyChecker.com and Prescription Justice | Jan 18, 2018 | Drug Safety
FDA Testing Lower-Cost Imported Medications
Tens of millions of people have bought medications from foreign pharmacies – despite the technical illegality of importing those medications. According to reporting by Kaiser Health News last month, the FDA tested imported medications, apparently to see if what Americans are doing is safe. All medications the FDA tested “contain[ed] the ingredients matching the medicines ordered.”
The Kaiser Health News reporting was focused on international pharmacy options offered by local governments, schools, and other self-insured organizations. While that’s interesting, it’s not breaking news (I mentioned it here). The FDA testing imports and saying the medications are safe, albeit begrudgingly, is breaking news. (more…)
Tagged with: drug imports, FDA, public education, testing, transparency
by Gabriel Levitt, President, PharmacyChecker.com and Prescription Justice | Jan 8, 2018 | Politics and policy
Last month, I published an op-ed in The Guardian in opposition to Alex Azar for Secretary of Health and Human Services. In advance of the Senate Finance Committee Hearing tomorrow over his nomination, I’m publishing my article in its entirety below.
Recently, the president announced Alex Azar as his nominee to lead the US Department of Health and Human Services, saying: “He will be a star for better healthcare and lower drug prices!” People like me – experts in drug policy and advocates for lowering drug costs for American patients – know that nothing could be farther from the truth.
On average, Americans pay twice as much for life-saving drugs as consumers in other developed countries. It doesn’t have to be this way, but unfortunately, Azar might think so.
On Wednesday, Azar appeared before the Senate Health, Education, Labor and Pensions committee. While he stated his commitment to lowering drug prices, he declined to support the two solutions that would have the greatest impact on patients. In fact, he and his company have vigorously opposed policies that would make healthcare more affordable for the rest of us. (more…)
Tagged with: Alex Azar, Eli Lilly, HHS, levitt op-ed, the guardian
